Partnerships Are Key To Foundation Medicine's Success

Since receiving approval for the first broad-panel diagnostic test as a combination product to detect cancer, Foundation Medicine has ramped up its partnerships with pharmaceutical companies and other stakeholders. The company expects to receive a similar approval for a broad-panel liquid biopsy genomic test in the first half of 2020.

Gaurav Singal Foundation Medicine
Gaurav Singal, Foundation Medicine's chief data officer, discussed the company's successful FDA product applications and CMS reimbursements. • Source: Foundation Medicine

Over the past few years the next-generation sequencing (NGS) company Foundation Medicine Inc. has achieved some major regulatory successes attributed to the company's ability to develop partnerships with key players in the healthcare ecosystem. In an interview with Medtech Insight, the company's data chief discussed its philosophy, approach to partnerships and vision for the future.

In December 2017, the US Food and Drug Administration approved Foundation Medicine's solid tissue gene diagnostic test FoundationOne CDx. It was the first companion broad-panel diagnostic test approved by the...

More from Business

More from Medtech Insight